左心室辅助装置术后晚期右心衰竭的演变及其与结局的关联
基于STS Intermacs数据库中2014年6月至2017年3月植入连续流LVAD且无同期RVAD、随访至少3个月的6118例患者,采用2014年修订的RHF定义分析晚期RHF的患病率、严重程度及3个月时RHF状态与12个月结局的关联。结果显示3、6、12个月轻度RHF发生率分别为5%、6%、6%,中度均为5%、3%、3%;3个月无RHF者后续RHF发生率低,且12个月死亡率、卒中、消化道出血和再住院累积发生率均显著低于轻度和中度RHF。
要点
- LVAD术后3个月无RHF者12个月死亡率6.9%,轻度16.7%,中度28.1%
- 3个月无RHF者12个月卒中、消化道出血和再住院累积发生率均更低
- LVAD术后12个月约十分之一患者出现轻度或中度晚期RHF,且预后更差
核心结论
- LVAD支持3个月后存活的患者中,12个月时近十分之一出现轻度或中度RHF,晚期RHF与更差生存及更高主要不良事件累积发生率相关。
研究设计与样本
- 回顾性队列分析STS Intermacs数据库中2014年6月2日至2017年3月31日植入连续流LVAD、无同期RVAD且随访至少3个月的患者,共6118例。
主要发现
- 3、6、12个月轻度RHF发生率分别为5%、6%、6%,中度分别为5%、3%、3%。
- 3个月无RHF者后续6和12个月RHF发生率低。
- 3个月无RHF compared with轻度 and中度RHF,12个月死亡累积发生率分别为6.9%、16.7%、28.1%(P < 0.0001)。
- 12个月卒中累积发生率分别为7.4%、9.5%、11.0%(P = 0.0095)。
- 12个月消化道出血累积发生率分别为14.8%、24.2%、23.6%(P < 0.0001),再住院分别为65.2%、73.2%、71.2%(P < 0.0001)。
关键数值与推荐
- RHF定义为中央静脉压升高的记录和表现同时存在。
临床怎么用
- LVAD术后3个月时应评估RHF状态,无RHF者后续事件风险较低,出现轻度或中度RHF者需加强随访和不良事件监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A revised definition of right heart failure (RHF) for the Society of Thoracic Surgeons Intermacs database of left ventricular assist devices (LVADs) was introduced in June 2014. OBJECTIVES: The purpose of this study was to determine the prevalence and severity of RHF over time and the association of RHF status at 3 months with 12-month outcomes after LVAD. METHODS: All patients in Society of Thoracic Surgeons Intermacs with follow-up and supported at least 3 months with a continuous flow LVAD implanted between June 2, 2014 and March 31, 2017 without a simultaneous RVAD. RHF was defined as both documentation and manifestations of elevated central venous pressures. RESULTS: There were 6,118 patients included with an incidence of RHF at 3, 6, and 12 months postimplant categorized as mild in 5%, 6%, and 6% and moderate in 5%, 3%, and 3%, respectively. For those with no RHF at 3 months, there was a low incidence of subsequent RHF at 6 and 12 months. The lack of RHF at 3 months, compared with mild and moderate RHF, was associated with a lower 12-month cumulative incidence of mortality (6.9% vs 16.7% vs 28.1%; P < 0.0001) and a lower 12-month cumulative incidence of stroke (7.4% vs 9.5% vs 11.0%; P = 0.0095), gastrointestinal bleeding (14.8% vs 24.2% vs 23.6%; P < 0.0001), and rehospitalization (65.2% vs 73.2% vs 71.2%; P < 0.0001). CONCLUSIONS: In patients surviving 3 months with LVAD support alone, mild or moderate RHF occurred in nearly 1 of 10 patients at 12 months. Patients with late RHF had worse survival and a higher cumulative incidence of major adverse events.
引用
- Rame, Pagani, Kiernan, et al. Evolution of Late Right Heart Failure With Left Ventricular Assist Devices and Association With Outcomes. J Am Coll Cardiol. 2021. PMID: 34857091. doi:10.1016/j.jacc.2021.09.1362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。